Completed PHASE2 INTERVENTIONAL NCT00029614

Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

Psychopharmacology of Adolescents With AUD and ADHD

Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Conditions Attention Deficit Hyperactivity Disorder Substance Use Disorders

Interventions Atomoxetine

Updated 5 times since 2017 Last updated: Apr 27, 2010 Started: May 31, 2006 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Attention Deficit Hyperactivity Disorder and Substance Use Disorders, this trial is completed. The trial is conducted by National Institute on Alcohol Abuse and Alcoholism (NIAAA) and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
University of Pittsburgh

Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States